AstraZeneca Pharmaceuticals LP

AstraZeneca Pharmaceuticals LP (USA) holds 5 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 5 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 5 FDA-registered manufacturing sites. 41 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “AstraZeneca Pharmaceuticals LP: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/astrazeneca-pharmaceuticals-lp

Overview

AstraZeneca Pharmaceuticals LP is a global, science-led biopharmaceutical company at the forefront of innovative research across various therapeutic areas. It is a subsidiary of AstraZeneca PLC.

Therapeutic areas

OncologyCardiovascularRenal & MetabolismRespiratoryImmunologyInfection & Vaccines

Active ingredients with DMF or CEP filings

Substances for which AstraZeneca Pharmaceuticals LP holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

AstraZeneca Pharmaceuticals LP holds 5 active (9 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • AZD2292Active2022-10-21
  • BUDESONIDEActive2018-10-10
  • GOSERELIN ACETATE IMPLANTActive2017-04-21
  • GOSERELIN ACETATEActive2017-04-21
  • METOPROLOL SUCCINATE EXTENDED RELEASE TABLETSActive2016-12-05
  • METOPROLOL SUCCINATE EXTENDED RELEASE/HYDROCHLOROTHIAZIDE 25/12.5,50/12.5 AND100/12.5 TABLETSInactive2014-05-21
  • LISINOPRIL BULK DRUGInactive1994-04-08
  • ATENOLOL ACETATEInactive1987-08-06
  • ATENOLOLInactive1987-03-30

Excipient Drug Master Files

AstraZeneca Pharmaceuticals LP holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.

  • POROUS PARTICLESActive2015-05-27

Registered manufacturing sites (5)

Physical sites registered with the US FDA and resolved to AstraZeneca Pharmaceuticals LP, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

41 FDA enforcement records linked to this company.

  • 4832026-06-26

    Cleaning / Sanitizing / Maintenance

  • recall — Class II2025-10-22

    Lack of Assurance of Sterility:

  • 4832024-05-31

    Complete Test Data

  • 4832024-05-31

    Procedures not in writing, fully followed

  • 4832024-05-31

    Investigations of discrepancies, failures

  • 4832024-05-31

    Complaint Handling Procedure

  • 4832023-09-19

    Written in-process control procedures

  • 4832023-09-19

    Complete Test Data

  • warning_letter2023-08-04

    FDA Warning Letter (drug product)

  • 4832022-07-22

    Procedures for sterile drug products

  • 4832022-07-22

    Equipment Design, Size and Location

  • 4832022-07-22

    Extent of discrepancy, failure investigations

  • recall — Class III2018-03-14

    Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).

  • 4832018-01-30

    Late submission of 15-day report

  • 4832017-08-24

    Complaint Handling Procedure

  • 4832017-08-24

    Procedures not in writing, fully followed

  • recall — Class I2017-07-19

    Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

  • recall — Class II2016-03-30

    Defective Delivery System: Some units have actuation counters set to a number other than 60.

  • recall — Class II2015-06-24

    Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR tablets.

  • 4832014-08-27

    Written procedures fail to include

  • recall — Class II2013-08-14

    Presence of Precipitate; potential for incomplete constitution upon addition of diluent.

  • 4832013-03-20

    Late submission of 15-day report

  • 4832011-10-28

    Written in-process control procedures

  • 4832011-10-28

    Absence of Written Procedures

  • 4832011-07-05

    Investigations of discrepancies, failures

  • 4832010-06-23

    Written record of investigation incomplete

  • 4832010-06-23

    Procedures for sterile drug products

  • 4832010-06-23

    Procedures not in writing, fully followed

  • 4832010-06-23

    Complaint Investigation/Follow-Up Findings

  • 4832010-06-23

    Annual visual exams of drug products

  • 4832009-12-07

    Training--operations, GMPs, written procedures

  • 4832009-12-07

    Procedures for sterile drug products

  • 4832009-12-07

    Procedures not in writing, fully followed

  • 4832009-12-07

    Establishment of time limitations

  • 4832009-12-07

    Written record of investigation incomplete

  • 4832009-12-07

    Investigations of discrepancies, failures

  • 4832009-12-07

    Changes to Procedures Not Reviewed, Approved

  • 4832009-12-07

    Absence of Written Procedures

  • 4832009-06-16

    In-process materials specifications

  • 4832009-06-16

    Procedures for sterile drug products

  • 4832009-06-16

    Procedure Deviations Recorded and Justified

For suppliers

Is this AstraZeneca Pharmaceuticals LP?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.